



Ghana



African Region

Based on 2015 reported data


I. Epidemiological profile

| Population (UN) | 2016 | % | Parasites and vectors |
|--|------------|-----|---|
| High transmission (> 1 case per 1000 population) | 28,200,000 | 100 | Plasmodium species: <i>P. falciparum</i> (99%), <i>P. vivax</i> (0%) |
| Low transmission (0-1 cases per 1000 population) | - | - | Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i> , <i>An. arabiensis</i> |
| Malaria-free (0 cases) | - | - | Reported confirmed cases (health facility): 4,535,167 Estimated cases: 8,060,000 [5,300,000-11,950,000] |
| Total | 28,210,000 | - | Confirmed cases at community level: 0 |
| | | | Reported deaths: 1,264 Estimated deaths: 12,880 [11,510-14,250] |


II. Intervention policies and strategies

| Intervention | Policies/strategies | Yes/No | Adopted | Antimalarial treatment policy | Medicine | Year adopted | | | | | |
|----------------|--|-----------|---------|---|------------|------------------|--------|-----|--------------|--|----------------------|
| ITN | ITNs/ LLINs distributed free of charge | Yes | 2004 | First-line treatment of unconfirmed malaria | AS+AQ | 2004 | | | | | |
| | ITNs/ LLINs distributed to all age groups | Yes | 2010 | First-line treatment of <i>P. falciparum</i> | AL; AS+AQ | 2004 | | | | | |
| IRS | IRS is recommended | Yes | 2005 | Treatment failure of <i>P. falciparum</i> | QN | 2004 | | | | | |
| | DDT is authorized for IRS | No | - | Treatment of severe malaria | AS; AM; QN | 2004 | | | | | |
| Larval control | Use of larval control recommended | Yes | 1999 | Treatment of <i>P. vivax</i> | - | - | | | | | |
| IPT | IPT used to prevent malaria during pregnancy | Yes | 2003 | Dosage of Primaquine for radical treatment of <i>P. vivax</i> | - | - | | | | | |
| Diagnosis | Patients of all ages should receive diagnostic test | Yes | 2008 | Type of RDT used | - | <i>P. f</i> only | | | | | |
| | Malaria diagnosis is free of charge in the public sector | No | - | | | | | | | | |
| Treatment | ACT is free of charge for all ages in public sector | No | - | Therapeutic efficacy tests (clinical and parasitological failure, %) | | | | | | | |
| | The sale of oral artemisinin-based monotherapies (oAMTs) | Is banned | 2006 | Medicine | Year(s) | Min | Median | Max | Follow-up | No. of studies | Species |
| | Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i> | No | - | AL | 2010-2014 | 0 | 0 | 9.4 | 28 days | 9 | <i>P. falciparum</i> |
| | Primaquine is used for radical treatment of <i>P. vivax</i> | No | - | AS+AQ | 2010-2014 | 0 | 0 | 3.8 | 28 days | 11 | <i>P. falciparum</i> |
| | G6PD test is a requirement before treatment with primaquine | No | - | Insecticide resistance tests (mosquito mortality, %) | | | | | | | |
| | Directly observed treatment with primaquine is undertaken | No | - | Insecticide class | Years | Min | Mean | Max | No. of sites | Species | |
| | System for monitoring adverse reactions to antimalarials exists | Yes | 2001 | Organochlorines | 2010-2016 | 0 | 0.2 | 0.7 | 36 | <i>An. coluzzii</i> , <i>An. funestus s.l.</i> , + other | |
| Surveillance | ACD for case investigation (reactive) | No | - | Carbamates | 2010-2016 | 0 | 0.8 | 1 | 40 | <i>An. coluzzii</i> , <i>An. funestus s.l.</i> , + other | |
| | ACD of febrile cases at community level (pro-active) | No | - | Organophosphates | 2010-2016 | 0.3 | 0.9 | 1 | 45 | <i>An. coluzzii</i> , <i>An. funestus s.l.</i> , + other | |
| | Mass screening is undertaken | No | - | Pyrethroids | 2010-2016 | 0 | 0.5 | 1 | 46 | <i>An. coluzzii</i> , <i>An. funestus s.l.</i> , + other | |
| | Uncomplicated <i>P. falciparum</i> cases routinely admitted | No | - | | | | | | | | |
| | Uncomplicated <i>P. vivax</i> cases routinely admitted | No | - | | | | | | | | |
| | Foci and case investigation undertaken | - | - | | | | | | | | |
| | Case reporting from private sector is mandatory | No | - | | | | | | | | |


III. Financing




Government expenditure by intervention in 2016





IV. Coverage




Cases tested and treated in public sector



V. Impact



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

